DK200700007A - Farmaceutisk præparat indeholdende en stabil og klar oplösning af antiinflammatorisk læge-middel i blöd gelatinekapsel og fremgangsmåde til fremstilling deraf - Google Patents
Farmaceutisk præparat indeholdende en stabil og klar oplösning af antiinflammatorisk læge-middel i blöd gelatinekapsel og fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK200700007A DK200700007A DK200700007A DKPA200700007A DK200700007A DK 200700007 A DK200700007 A DK 200700007A DK 200700007 A DK200700007 A DK 200700007A DK PA200700007 A DKPA200700007 A DK PA200700007A DK 200700007 A DK200700007 A DK 200700007A
- Authority
- DK
- Denmark
- Prior art keywords
- weight
- pharmaceutical composition
- approx
- soft gelatin
- gelatin capsule
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 19
- 239000007903 gelatin capsule Substances 0.000 title claims 14
- 239000002260 anti-inflammatory agent Substances 0.000 title claims 5
- 229940124599 anti-inflammatory drug Drugs 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 3
- 238000002360 preparation method Methods 0.000 title claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 108010010803 Gelatin Proteins 0.000 claims 6
- 238000012377 drug delivery Methods 0.000 claims 6
- 229920000159 gelatin Polymers 0.000 claims 6
- 239000008273 gelatin Substances 0.000 claims 6
- 235000019322 gelatine Nutrition 0.000 claims 6
- 235000011852 gelatine desserts Nutrition 0.000 claims 6
- 239000008213 purified water Substances 0.000 claims 6
- VTGPMVCGAVZLQI-UHFFFAOYSA-M sodium;2-[4-(2-methylpropyl)phenyl]propanoate;dihydrate Chemical compound O.O.[Na+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 VTGPMVCGAVZLQI-UHFFFAOYSA-M 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 235000011187 glycerol Nutrition 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 4
- 229930003427 Vitamin E Natural products 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 3
- 235000019441 ethanol Nutrition 0.000 claims 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 3
- 235000019165 vitamin E Nutrition 0.000 claims 3
- 229940046009 vitamin E Drugs 0.000 claims 3
- 239000011709 vitamin E Substances 0.000 claims 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 2
- 239000008137 solubility enhancer Substances 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
1. Farmaceutisk præparat, der omfatter: en i det væsentlige stabil og klar opløsning af et antiinflammatorisk lægemiddel i en blød gelatinekapsel, hvor opløsningen omfatter: natriumdihydratsalt af Ibuprofen; et solubiliseringsmiddel; et co-solubiliseringsmiddel; opløseiighedsfremmende middel; og en antioxidant.
2. Farmaceutisk præparat ifølge krav 1, hvor solubiliseringsmidlet er oliesyre, diethy-lenglycol-monoethyiether, ethylalkohol.
3. Farmaceutisk præparat ifølge krav 1, hvor co-solubiliseringsmidlet er propylenglycol, polyethylenglycol.
4. Farmaceutisk præparat ifølge krav 1, hvor det opløseiighedsfremmende middel er polyvinylpyrrolidon, propylenglycol.
5. Farmaceutisk præparat ifølge krav 1, hvor antioxidanten er vitamin E.
6. Farmaceutisk præparat, der omfatter: en i det væsentlige stabil og klar opløsning af et antiinflammatorisk lægemiddel i en blød gelatinekapsel, hvor opløsningen omfatter: ca. 30,0 til 35,0 vægtprocent Ibuprofen-natriumdihydrat; ca. 55,0 til 65,0 vægtprocent oliesyre; ca. 0,6 til 1,2 vægtprocent polyvinylpyrrolidon; ca. 4,0 til 5,0 vægtprocent propylenglycol; og ca. 0,3 til 0,7 vægtprocent vitamin E som antioxidant.
7. Farmaceutisk præparat, der omfatter: en i det væsentlige stabil og klar opløsning af et antiinflammatorisk lægemiddel i en blød gelatinekapsel, hvor opløsningen omfatter: ca. 20,0 til 22,0 vægtprocent Ibuprofen-natriumdihydrat; ca. 70,0 til 75,0 vægtprocent diethylenglycol-monoethylether; ca, 0,8 til 1,2 vægtprocent polyvinylpyrrolidon; og ca. 3,0 ti! 5,0 vægtprocent propylenglycol.
8. Farmaceutisk præparat, der omfatter: en i det væsentlige stabil og klar opløsning af et antiinflammatorisk lægemiddel i en blød gelatinekapsel, hvor opløsningen omfatter: ca. 28,0 til 30,0 vægtprocent Ibuprofen-natriumdihydrat; ca, 9,0 til 11,0 vægtprocent ethylalkohol; ca. 4,0 til 6,0 vægtprocent propylenglycol; og ca. 50,0 til 60,0 vægtprocent polyethylenglycol 400.
9. Fremgangsmåde til fremstilling af et farmaceutisk præparat ifølge et hvilket som helst af kravene 1 -8, hvilken fremgangsmåde omfatter: tilsætning af polyvinylpyrrolidon til propylenglycol med konstant blanding; tilsætning af Ibuprofen-natriumdihydrat til opløsningen med kontinuerlig blanding; tilsætning af vitamin E til det resulterende og yderligere blanding for at få en klar opløsning; og anbringelse af den resulterende opløsning i bløde gelatinekapsler.
10. Fremgangsmåde til fremstilling af et farmaceutisk præparat ifølge et hvilket som helst af kravene 1 -8, hvilken fremgangsmåde omfatter: solubilisering af polyvinylpyrrolidon i propylenglycol med blanding; tilsætning af diethylenglycol-monoethylether til blanding og yderligere blanding; tilsætning af Ibuprofen-natriumdihydrat til det resulterende og yderligere blanding; og anbringelse af den resulterende opløsning i bløde gelatinekapsler.
11. Fremgangsmåde til fremstilling af et farmaceutisk præparat ifølge et hvilket som helst af kravene 1-8, hvilken fremgangsmåde omfatter: tilsætning af propylenglycol og ethylalkohol til polyethylenglycol 400 og blanding; tilsætning af Ibuprofen-natriumdihydrat til blandingen og yderligere blanding; og anbringelse af den resulterende opløsning i bløde gelatinekapsler.
12. Oralt administrerbart farmaceutisk præparat ifølge et hvilket som helst af kravene 1-11, hvilket præparat er udformet som en forbedret lægemiddelafgivelsesindretning, der omfatter en blød gelatinekapsel med en skal omfattende ca. 45,0 vægtprocent gelatine, ca. 20 vægtprocent glycerin og ca. 35 vægtprocent renset vand.
13. Oralt administrerbart farmaceutisk præparat ifølge et hvilket som helst af kravene 1-11, hvilket præparat er udformet som en forbedret lægemiddelafgivelsesindretning, der omfatter en blød gelatinekapsel med en skal omfattende ca. 45,0 vægtprocent gelatine, ca. 14 vægtprocent glycerin, ca. 9 vægtprocent sorbitolopløsning og ca. 32 vægtprocent renset vand.
14. Oralt administrerbart farmaceutisk præparat ifølge et hvilket som helst af kravene 1-11, hvilket præparat er udformet som en forbedret lægemiddelafgivelsesindretning, der omfatter en blød gelatinekapsel med en skal omfattende ca. 50,0 vægtprocent gelatine, ca. 18 vægtprocent glycerin og ca. 32 vægtprocent renset vand.
15. Oralt administrerbart farmaceutisk præparat ifølge et hvilket som helstaf kravene 1-11, hvilket præparat er udformet som en forbedret lægemiddelafgivelsesindretning, der omfatter en blød gelatinekapsel med en skal omfattende ca. 40,0 vægtprocent gelatine, ca. 16 vægtprocent glycerin og ca. 44 vægtprocent renset vand.
16. Oralt administrerbart farmaceutisk præparat ifølge et hvilket som helst af kravene 1-11, hvilket præparat er udformet som en forbedret lægemiddelafgivelsesindretning, der omfatter en blød gelatinekapsel med en skal omfattende ca. 48,0 vægtprocent gelatine, ca. 20 vægtprocent Anidrisorb 85/70 og ca. 32 vægtprocent renset vand.
17. Oralt administrerbart farmaceutisk præparat ifølge et hvilket som helst af kravene 1-11, hvilket præparat er udformet som en forbedret lægemiddelafgivelsesindretning, der omfatter en blød gelatinekapsel med en skal omfattende ca. 45,0 vægtprocent gelatine, ca. 14 vægtprocent glycerin, ca. 9 vægtprocent Anidrisorb 85/70 og ca. 32 vægtprocent renset vand.
18. Farmaceutisk præparat i det væsentlige som beskrevet heri med henvisning til beskrivelsen og eksemplerne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2004/000158 WO2005120459A2 (en) | 2004-06-07 | 2004-06-07 | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
| IN2004000158 | 2004-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200700007A true DK200700007A (da) | 2007-01-24 |
Family
ID=35503636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200700007A DK200700007A (da) | 2004-06-07 | 2007-01-04 | Farmaceutisk præparat indeholdende en stabil og klar oplösning af antiinflammatorisk læge-middel i blöd gelatinekapsel og fremgangsmåde til fremstilling deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060286164A1 (da) |
| AU (1) | AU2004320488A1 (da) |
| BR (1) | BRPI0418885A (da) |
| CA (1) | CA2570649A1 (da) |
| DK (1) | DK200700007A (da) |
| GB (1) | GB2429916A (da) |
| MX (1) | MXPA06014185A (da) |
| PL (1) | PL381799A1 (da) |
| WO (1) | WO2005120459A2 (da) |
| ZA (1) | ZA200610513B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080317684A1 (en) * | 2006-09-06 | 2008-12-25 | Isw Group, Inc. | Topical Compositions |
| US9914968B2 (en) | 2012-09-26 | 2018-03-13 | Cepheid | Honeycomb tube |
| FR2997856B1 (fr) * | 2012-11-14 | 2015-04-24 | Pf Medicament | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
| US9622970B2 (en) * | 2014-05-08 | 2017-04-18 | Yaguang Liu | Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| GB2595301B (en) * | 2020-05-21 | 2025-01-08 | Reckitt Benckiser Health Ltd | Novel Formulation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3437599C2 (de) * | 1984-10-13 | 1987-04-16 | Dolorgiet GmbH & Co KG, 5205 St Augustin | Ibuprofen enthaltende Weichgelatinekapseln |
| US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| US5519057A (en) * | 1986-11-14 | 1996-05-21 | Johnson & Johnson--Merck Pharmaceuticals Co. | Ibuprofen-containing medicament |
| GB8813682D0 (en) * | 1988-06-09 | 1988-07-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
| DK0584108T3 (da) * | 1991-05-13 | 2000-10-09 | Boots Co Plc | Farmaceutisk præparat omfattende ibuprofensalt |
| IT1264855B1 (it) * | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici |
| US6221391B1 (en) * | 1998-11-23 | 2001-04-24 | Accucaps Industries Limited | Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith |
| KR100602725B1 (ko) * | 1998-12-11 | 2006-07-20 | 파마솔루션스, 인코포레이티드 | 물에서 불충분하게 용해되는 약제를 위한 자가-유화용조성물 |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6251426B1 (en) * | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
-
2004
- 2004-06-07 MX MXPA06014185A patent/MXPA06014185A/es not_active Application Discontinuation
- 2004-06-07 AU AU2004320488A patent/AU2004320488A1/en not_active Abandoned
- 2004-06-07 BR BRPI0418885-3A patent/BRPI0418885A/pt not_active IP Right Cessation
- 2004-06-07 GB GB0624498A patent/GB2429916A/en not_active Withdrawn
- 2004-06-07 US US10/545,601 patent/US20060286164A1/en not_active Abandoned
- 2004-06-07 ZA ZA200610513A patent/ZA200610513B/en unknown
- 2004-06-07 PL PL381799A patent/PL381799A1/pl not_active Application Discontinuation
- 2004-06-07 WO PCT/IN2004/000158 patent/WO2005120459A2/en not_active Ceased
- 2004-06-07 CA CA002570649A patent/CA2570649A1/en not_active Abandoned
-
2007
- 2007-01-04 DK DK200700007A patent/DK200700007A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2570649A1 (en) | 2005-12-22 |
| US20060286164A1 (en) | 2006-12-21 |
| ZA200610513B (en) | 2008-06-25 |
| PL381799A1 (pl) | 2007-07-09 |
| MXPA06014185A (es) | 2007-04-16 |
| BRPI0418885A (pt) | 2007-11-27 |
| WO2005120459A3 (en) | 2006-03-09 |
| WO2005120459A2 (en) | 2005-12-22 |
| GB0624498D0 (en) | 2007-01-17 |
| GB2429916A (en) | 2007-03-14 |
| AU2004320488A1 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI285644B (en) | A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant | |
| US5641512A (en) | Soft gelatin capsule compositions | |
| ES2620413T3 (es) | Formulaciones veterinarias antihelmínticas tópicas | |
| EP1207872B1 (en) | Ibuprofen-containing softgels | |
| WO2004054540A3 (en) | Solid compositions with improved bio-availability of insoluble or poorly water soluble drugs and a corresponding process for preparing such | |
| WO2009069139A1 (en) | Dosage form providing an ibuprofen-containing liquid fill | |
| KR960703576A (ko) | 고농축 아세트아미노펜 용액을 함유하는 젤라틴 캡슐(gelatin capsules containing a highly concentrated acetaminophen solution) | |
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| CN105395528A (zh) | 依匹哌唑口腔速溶膜 | |
| MEP10808A (en) | Solid drug for oral use | |
| US20120183608A1 (en) | Highly concentrated liquid acetaminophen solutions | |
| WO2010044093A1 (en) | Formulations containing rifaximin | |
| EP3033085A1 (en) | Dosage form comprising enzalutamide | |
| CA2600023A1 (en) | Solvent system for enhancing the solubility of pharmaceutical agents | |
| EP1485081B1 (en) | Ibuprofen solution for hard shell capsules | |
| ES2761868T3 (es) | Cápsula blanda de 2,2,6,6-tetraisopropil-4,4-2-bifenol y método para la preparación de la misma | |
| HRP20150918T1 (hr) | Poboljšana stabilna vodena formulacija (e)-4-karboksistiril-4-klorobenzil sulfona | |
| CA2954392A1 (en) | Diclofenac sublingual spray | |
| ES2909797T3 (es) | Composición farmacéutica de derivado de aminodihidrotiazina condensado | |
| WO2016084099A1 (en) | Soft gelatin capsule composition of anti-tussive agents | |
| WO2014092661A1 (en) | Particulate formulations of tadalafil in effervescent form | |
| JP5840668B2 (ja) | ロキソプロフェンナトリウム含有軟カプセル用内容物、及び、それを含有する軟カプセル製剤 | |
| US20150010622A1 (en) | Capsule formulation comprising fexofenadine | |
| ES2391775T3 (es) | Formulación farmacéutica para aumentar la solubilidad de compuestos de 10-hidroxicamptotecina en disolventes polares no acuosos | |
| US20060286164A1 (en) | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |